These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1381 related articles for article (PubMed ID: 26135703)

  • 21. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
    Mease PJ; van der Heijde D; Ritchlin CT; Okada M; Cuchacovich RS; Shuler CL; Lin CY; Braun DK; Lee CH; Gladman DD;
    Ann Rheum Dis; 2017 Jan; 76(1):79-87. PubMed ID: 27553214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
    Gottlieb A; Menter A; Mendelsohn A; Shen YK; Li S; Guzzo C; Fretzin S; Kunynetz R; Kavanaugh A
    Lancet; 2009 Feb; 373(9664):633-40. PubMed ID: 19217154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.
    Baraliakos X; Gossec L; Pournara E; Jeka S; Mera-Varela A; D'Angelo S; Schulz B; Rissler M; Nagar K; Perella C; Coates LC
    Ann Rheum Dis; 2021 May; 80(5):582-590. PubMed ID: 33334727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study.
    McInnes IB; Mease PJ; Kivitz AJ; Nash P; Rahman P; Rech J; Conaghan PG; Kirkham B; Navarra S; Belsare AD; Delicha EM; Pricop L
    Lancet Rheumatol; 2020 Apr; 2(4):e227-e235. PubMed ID: 38268157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
    Papp KA; Weinberg MA; Morris A; Reich K
    Lancet; 2021 Apr; 397(10284):1564-1575. PubMed ID: 33894834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
    Pavelka K; Kivitz A; Dokoupilova E; Blanco R; Maradiaga M; Tahir H; Pricop L; Andersson M; Readie A; Porter B
    Arthritis Res Ther; 2017 Dec; 19(1):285. PubMed ID: 29273067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Venhoff N; Schmidt WA; Bergner R; Rech J; Unger L; Tony HP; Finzel S; Andreica I; Kofler DM; Weiner SM; Lamprecht P; Schulze-Koops H; App C; Pournara E; Mendelson MH; Sieder C; Maricos M; Thiel J
    Lancet Rheumatol; 2023 Jun; 5(6):e341-e350. PubMed ID: 38251601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.
    Smolen JS; Beaulieu A; Rubbert-Roth A; Ramos-Remus C; Rovensky J; Alecock E; Woodworth T; Alten R;
    Lancet; 2008 Mar; 371(9617):987-97. PubMed ID: 18358926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
    Ritchlin C; Rahman P; Kavanaugh A; McInnes IB; Puig L; Li S; Wang Y; Shen YK; Doyle MK; Mendelsohn AM; Gottlieb AB;
    Ann Rheum Dis; 2014 Jun; 73(6):990-9. PubMed ID: 24482301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
    Baeten D; Sieper J; Braun J; Baraliakos X; Dougados M; Emery P; Deodhar A; Porter B; Martin R; Andersson M; Mpofu S; Richards HB; ;
    N Engl J Med; 2015 Dec; 373(26):2534-48. PubMed ID: 26699169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies.
    Coates LC; Wallman JK; McGonagle D; Schett GA; McInnes IB; Mease PJ; Rasouliyan L; Quebe-Fehling E; Asquith DL; Fasth AER; Pricop L; Gaillez C
    Arthritis Res Ther; 2019 Dec; 21(1):266. PubMed ID: 31801620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
    McInnes IB; Kavanaugh A; Gottlieb AB; Puig L; Rahman P; Ritchlin C; Brodmerkel C; Li S; Wang Y; Mendelsohn AM; Doyle MK;
    Lancet; 2013 Aug; 382(9894):780-9. PubMed ID: 23769296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
    Mease PJ; Genovese MC; Greenwald MW; Ritchlin CT; Beaulieu AD; Deodhar A; Newmark R; Feng J; Erondu N; Nirula A
    N Engl J Med; 2014 Jun; 370(24):2295-306. PubMed ID: 24918373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study.
    Genovese MC; Durez P; Richards HB; Supronik J; Dokoupilova E; Aelion JA; Lee SH; Codding CE; Kellner H; Ikawa T; Hugot S; Ligozio G; Mpofu S
    J Rheumatol; 2014 Mar; 41(3):414-21. PubMed ID: 24429175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.
    Papp K; Warren RB; Green L; Reich K; Langley RG; Paul C; Asahina A; Johnson L; Arora V; Osuntokun O; Lebwohl M
    Lancet Rheumatol; 2023 Sep; 5(9):e542-e552. PubMed ID: 38251498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
    Hueber W; Sands BE; Lewitzky S; Vandemeulebroecke M; Reinisch W; Higgins PD; Wehkamp J; Feagan BG; Yao MD; Karczewski M; Karczewski J; Pezous N; Bek S; Bruin G; Mellgard B; Berger C; Londei M; Bertolino AP; Tougas G; Travis SP;
    Gut; 2012 Dec; 61(12):1693-700. PubMed ID: 22595313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 70.